Tags

Type your tag names separated by a space and hit enter

Immunogenicity of low dose prime-boost vaccination of mRNA vaccine CV07050101 in non-human primates.
bioRxiv. 2021 Jul 07B

Abstract

Many different vaccine candidates against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the etiological agent of COVID-19, are currently approved and under development. Vaccine platforms vary from mRNA vaccines to viral-vectored vaccines, and several candidates have been shown to produce humoral and cellular responses in small animal models, non-human primates and human volunteers. In this study, six non-human primates received a prime-boost intramuscular vaccination with 4 µg of mRNA vaccine candidate CV07050101, which encodes a pre-fusion stabilized spike (S) protein of SARS-CoV-2. Boost vaccination was performed 28 days post prime vaccination. As a control, six animals were similarly injected with PBS. Humoral and cellular immune responses were investigated at time of vaccination, and two weeks afterwards. No antibodies could be detected two and four weeks after prime vaccination. Two weeks after boost vaccination, binding but no neutralizing antibodies were detected in 4 out of 6 non-human primates. SARS-CoV-2 S protein specific T cell responses were detected in these 4 animals. In conclusion, prime-boost vaccination with 4 µg of vaccine candidate CV07050101 resulted in limited immune responses in 4 out of 6 non-human primates.

Authors+Show Affiliations

Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.Rocky Mountain Veterinary Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.Rocky Mountain Veterinary Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.CureVac AG, Tuebingen, Germany.Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.

Pub Type(s)

Preprint

Language

eng

PubMed ID

34268507

Citation

van Doremalen, Neeltje, et al. "Immunogenicity of Low Dose Prime-boost Vaccination of mRNA Vaccine CV07050101 in Non-human Primates." BioRxiv : the Preprint Server for Biology, 2021.
van Doremalen N, Fischer RJ, Schulz JE, et al. Immunogenicity of low dose prime-boost vaccination of mRNA vaccine CV07050101 in non-human primates. bioRxiv. 2021.
van Doremalen, N., Fischer, R. J., Schulz, J. E., Holbrook, M. G., Smith, B. J., Lovaglio, J., Petsch, B., & Munster, V. J. (2021). Immunogenicity of low dose prime-boost vaccination of mRNA vaccine CV07050101 in non-human primates. BioRxiv : the Preprint Server for Biology. https://doi.org/10.1101/2021.07.07.451505
van Doremalen N, et al. Immunogenicity of Low Dose Prime-boost Vaccination of mRNA Vaccine CV07050101 in Non-human Primates. bioRxiv. 2021 Jul 7; PubMed PMID: 34268507.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Immunogenicity of low dose prime-boost vaccination of mRNA vaccine CV07050101 in non-human primates. AU - van Doremalen,Neeltje, AU - Fischer,Robert J, AU - Schulz,Jonathan E, AU - Holbrook,Myndi G, AU - Smith,Brian J, AU - Lovaglio,Jamie, AU - Petsch,Benjamin, AU - Munster,Vincent J, Y1 - 2021/07/07/ PY - 2021/7/16/entrez PY - 2021/7/17/pubmed PY - 2021/7/17/medline JF - bioRxiv : the preprint server for biology JO - bioRxiv N2 - Many different vaccine candidates against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the etiological agent of COVID-19, are currently approved and under development. Vaccine platforms vary from mRNA vaccines to viral-vectored vaccines, and several candidates have been shown to produce humoral and cellular responses in small animal models, non-human primates and human volunteers. In this study, six non-human primates received a prime-boost intramuscular vaccination with 4 µg of mRNA vaccine candidate CV07050101, which encodes a pre-fusion stabilized spike (S) protein of SARS-CoV-2. Boost vaccination was performed 28 days post prime vaccination. As a control, six animals were similarly injected with PBS. Humoral and cellular immune responses were investigated at time of vaccination, and two weeks afterwards. No antibodies could be detected two and four weeks after prime vaccination. Two weeks after boost vaccination, binding but no neutralizing antibodies were detected in 4 out of 6 non-human primates. SARS-CoV-2 S protein specific T cell responses were detected in these 4 animals. In conclusion, prime-boost vaccination with 4 µg of vaccine candidate CV07050101 resulted in limited immune responses in 4 out of 6 non-human primates. UR - https://www.unboundmedicine.com/medline/citation/34268507/Immunogenicity_of_low_dose_prime_boost_vaccination_of_mRNA_vaccine_CV07050101_in_non_human_primates_ L2 - https://doi.org/10.1101/2021.07.07.451505 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.